Jaguar Health Seeks Shareholder Approval for Highly Dilutive Preferred Exchange, Warrant Repricing, and Equity Plan Expansion

summarizeSummary

Jaguar Health filed a preliminary proxy for a September 4 special meeting seeking approval for three highly dilutive actions: exchanging Series Q Preferred Stock for up to 90% more common shares, repricing warrants to $1.00 (adding 13% dilution), and expanding the equity plan to 14% of fully diluted shares.

check_boxKey Events · Corporate Governance and Compliance · JAGX

• Series Q Exchange Could Add 90% More Shares

  Proposal 1 seeks approval to issue up to 7,911,743 shares upon exchange of 889.28 Series Q Preferred shares. At a hypothetical $0.50 exchange price, 44.5 million shares would be issued — 90.2% of the current 4.86 million outstanding. Because the actual exchange price is the lower of the closing price or 5-day average before each exchange, dilution could be severe if the stock stays depressed.

• Warrant Repricing Adds 13% Dilution, Forces Quick Exercise

  Proposal 2 reprices 60,781 warrants from $35.00–$266.44 down to $1.00, and also entitles holders to 682,661 dividend shares from the Series O conversion. Total potential issuance is 745,354 shares (13.3% of outstanding). If approved, the warrants must be exercised within 30 days via cashless exercise, creating immediate selling pressure.

• Equity Plan Expansion to 14% of Fully Diluted Shares

  Proposal 3 amends the 2014 Stock Incentive Plan to increase the share reserve to 14% of fully diluted shares as of September 30, 2026. With only 10,591 shares currently available (0.17% of outstanding), the plan would otherwise run dry in Q3 2026. The new reserve will be calculated on a fully diluted basis including all convertible securities, meaning it could be substantial.

• Special Meeting Set for September 4, 2026

  Shareholders of record as of July 6, 2026 will vote on all three proposals at a special meeting in San Francisco. The board recommends voting FOR all proposals. Approval requires a majority of votes cast, except Proposal 1 where Series Q holders cannot vote.

auto_awesomeAnalysis · JAGX · Life Sciences

Shareholders face a triple threat of dilution as Jaguar Health puts three proposals to a vote. The first alone could swell the share count by up to 90% if the Series Q Preferred Stock is exchanged at a low price — the company's own example at $0.50 per share shows 44.5 million new shares on top of 4.86 million outstanding. A second proposal reprices deeply out-of-the-money warrants to $1.00, adding another 13% dilution, and forces a cashless exercise within 30 days of approval. The third reloads the equity incentive plan to 14% of fully diluted shares, ensuring management and employees can be compensated even as the share count balloons. With the stock already trading near its 52-week low of $0.95, these approvals would give the company the green light to issue shares at prices that could drive it even lower. The special meeting is set for September 4, 2026.